Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Theravance Biopharma (TBPH) EBITDA (2016 - 2025)

Theravance Biopharma (TBPH) has disclosed EBITDA for 13 consecutive years, with $20.0 million as the latest value for Q4 2025.

  • Quarterly EBITDA rose 317.52% to $20.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $64.9 million through Dec 2025, up 229.88% year-over-year, with the annual reading at -$3.6 million for FY2025, 92.33% up from the prior year.
  • EBITDA for Q4 2025 was $20.0 million at Theravance Biopharma, up from $3.7 million in the prior quarter.
  • The five-year high for EBITDA was $916.6 million in Q3 2022, with the low at -$79.7 million in Q1 2021.
  • Average EBITDA over 5 years is $30.2 million, with a median of -$13.1 million recorded in 2024.
  • The sharpest move saw EBITDA soared 2696.33% in 2022, then plummeted 100.97% in 2023.
  • Over 5 years, EBITDA stood at -$56.2 million in 2021, then soared by 68.96% to -$17.4 million in 2022, then soared by 64.2% to -$6.2 million in 2023, then tumbled by 47.44% to -$9.2 million in 2024, then skyrocketed by 317.52% to $20.0 million in 2025.
  • According to Business Quant data, EBITDA over the past three periods came in at $20.0 million, $3.7 million, and $54.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.